Table 3.

Treatment response in evaluable patients according to baseline platelet counts

	SUMMIT		CREST*
BPC less than 75 × 109/L	BPC 75 × 109/L or greater	BPC 75 × 109/L or greater
No. patients	35	157	26
CR, no. (%)	3 (9)	15 (10)	1 (4)
PR, no. (%)	8 (23)	26 (17)	9 (35)
MR, no. (%)	2 (6)	12 (8)	3 (12)
Overall response (CR, PR, MR), no. (%)	13 (37)	53 (34)	13 (50)

BPC indicates baseline platelet count; CR, complete response; PR, partial response; and MR, minor response.

^*No patient in CREST receiving bortezomib 1.3 mg/m² had a baseline platelet count less than 75 × 10⁹/L.